Although our study did not examine VSCC tumours for evidence of PTCH1 or SMO mutations, we speculate that overexpression of SHH ligand most likely constitutes the mechanism for pathway activation in VSCC, given that in cases where SHH was over-expressed, there was a corresponding upregulation of PTCH1 and GLI1. This evidence concerns the gene SMO and neoplasm.